Off Patent
October 2026

Saphris

asenapine maleate

Abbvie Inc

Tablet (sublingual) · NDA 022117

Last listed protection ended
October 6, 2026

The FDA listed 2 patents for Saphris, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,741,358
    Claims the drug substance, the drug product and a use (U-1064, U-1893, U-1960, U-1961, U-1962, U-1963, U-1966)
  2. Ended
    Patent 8,022,228
    Claims the drug substance and the drug product
  3. Ended
    Patent 7,741,358
    Pediatric extension: six more months
  4. Ended
    Patent 8,022,228
    Pediatric extension: six more months